Abstract:Insomnia is a highly prevalent condition, and due to ongoing demand from patients suffering with this condition, new pharmacological treatments are actively being sought. As our neurophysiological understanding of insomnia grows, so too do the available treatment options. A significant advance in the treatment of insomnia came with the development of the nonbenzodiazepine hypnotic medications, zolpidem, zaleplon and eszopiclone. These medications have shorter durations of action than many traditional benzodiazepines and may be associated with less risk of tolerance and abuse. They have also been demonstrated to be helpful in cases in which insomnia is comorbid with depression or anxiety, leading to beneficial effects not only with sleep but also with mood and anxiety symptoms. Melatonin, a naturally-occurring substance intimately involved in the regulation of the circadian rhythm, has also been explored as a hypnotic. Little data to date support its use; however, there is evidence that ramelteon, a melatonin agonist, may be helpful for sleep initiation difficulties. Tri-cyclic antidepressants have long been used for insomnia, but use has been limited by unwanted anticholinergic side effects. Low-dose doxepin, at doses of 3 and 6mg, has been demonstrated to have the unique property among its class of being free of anticholinergic effects at those doses. In addition, it seems to have particular efficacy for sleep maintenance insomnia, exhibiting the most robust effects in the latter third of the night. The hypocretin/orexin system has been identified as a possible target. Almorexant, a hypocretin/orexin antagonist displayed evidence of efficacy during Phase III clinical trials but these trials were recently discontinued due to its side effect profile. Another hypocretin/orexin antagonist with a different mechanism of action, MK-4035, is presently in clinical trials. Serotonin antagonists and inverse agonists have been investigated; however, a recent trial with APD125 was discontinued due to lack of efficacy. Sodium oxybate has been used off-label for insomnia by some providers, although data supporting its use are limited. While the sleep-promoting effects of GABA(A) (nonbenzodiazepines and benzodiazepines) enhancement is well-established, newer research examining other mechanisms of action suggest that agents which modulate the histaminergic, serotonergic, melontonergic, and hypocretin/orexin and perhaps GABA-B systems show promise.

P.3.c.003 A Randomized, Controlled Study to Evaluate Quetiapine Fumarate in Improving Sleep Quality of Schizophrenia

Antipsychotic medications and sleep problems in patients with schizophrenia

0372 Quetiapine Effect on Sleep, Breathing, and Next Day Performance in People with OSA and Difficulty Maintaining Sleep

Clozapine and objective assessment of hypersomnolence in patients with schizophrenia: a systematic review

[Effects of Risperidone on Polysomnography in Patients with First-Episode Schizophrenia].

Clinical study of quetiapine and clozapine in the treatment of schizophrenia

Efficacy and Tolerability of Once-Daily Extended Release Quetiapine Fumarate in Acute Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study.

Effects Of Olanzapine, Quetiapine, And Risperidone On Neurocognitive Function In Early Psychosis: A Randomized, Double-Blind 52-Week Comparison

Study on the Effect of Zopiclone and Eszopiclone in the Treatment of Insomniac Patients by Polysomnogram

Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study

EFFICACY AND TOLERABILITY OF QUETIAPINE XR 400/600/800MG/DAY IN ACUTE SCHIZOPHRENIA: A POST-HOC ANALYSIS OF DATA FROM TWO POOLED RANDOMISED STUDIES

C.06.01 is Schizophrenia a Progressive Brain Disease?

Eszopiclone for the Treatment of Primary Insomnia: a Systematic Review and Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials

Commercial Chinese polyherbal preparation Zao Ren An Shen prescription for primary insomnia: a systematic review with meta-analysis and trial sequential analysis

Randomized controlled 16-week trial of the effect of quetiapine on the quality of life and cognitive functioning of patients in acute episodes of schizophrenia

A preliminary study of the effect of zopiclone and triazolam on polysomnograms

Pharmacological advances in the treatment of insomnia

A Randomized Double-Blind Controlled Study on the Efficacy of Quetiapine and Chlorpromazine in Treatment of Schizophrenia

Effect of Triazolam on Polysomnography in Patients with Insomnia

The Efficacy and Safety of Flexible Doses of Paliperidone Extended-Release Tablets in the Treatment of Acute Schizophrenia: a Randomized, Double Blind Olanzapine-Controlled Study

Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response—a prospective open-label study